Aurantiamide

Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models[1][2][3][4][5].

Product Specifications

CAS Number

[58115-31-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Mixed Lineage Kinase; NF-κB; RIP kinase

Type

Natural Products

Related Pathways

Apoptosis; MAPK/ERK Pathway; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/aurantiamide.html

Purity

99.56

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@H](CO)CC1=CC=CC=C1)[C@@H](NC(C2=CC=CC=C2)=O)CC3=CC=CC=C3

Molecular Formula

C25H26N2O3

Molecular Weight

402.49

Precautions

H302, H315, H319

References & Citations

[1]He RB, et al. Aurantiamide mitigates acute kidney injury by suppressing renal necroptosis and inflammation via GRPR-dependent mechanism.|[2]Shen H, et al. Aurantiamide suppresses the activation of NLRP3 inflammasome to improve the cognitive function and central inflammation in mice with Alzheimer's disease. CNS Neurosci Ther. 2023 Apr;29 (4) :1075-1085.|[3]Shen H, et al. Aurantiamide promotes M2 polarization of microglial cells to improve the cognitive ability of mice with Alzheimer's disease. Phytother Res. 2023 Jan;37 (1) :101-110.|[4]Aslan M, et al. Effects of aurantiamide on a rat model of renovascular arterial hypertension. Pflugers Arch. 2023 Oct;475 (10) :1177-1192.|[5]Lijiang Chen, et al. Pharmacokinetics and Biodistribution of Aurantiamide and Aurantiamide Acetate in Rats After Oral Administration of Portulaca Oleracea L. Extracts. J Agric Food Chem. 2016 May 4;64 (17) :3445-55.